NCT05808192 is a clinical trial of Immunosuppressive in Single Transplant, sponsored by University of Rome Tor Vergata.

Who is sponsoring NCT05808192?

NCT05808192 is sponsored by University of Rome Tor Vergata.

What drugs are being tested in NCT05808192?

Interventions in NCT05808192: Immunosuppressive.

What condition does NCT05808192 study?

NCT05808192 studies Single Transplant, 5 Years of Follow-up After Transplant, in Which an Attempt Was Made to Suspend IS.

Is NCT05808192 still recruiting?

NCT05808192 is currently completed. Last updated 11 April 2023.

Last reviewed 2023-04-11 · How we verify

NCT05808192

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

De Novo Metabolic Syndrome in Liver Transplant Patients After Immunosuppression Withdrawal

Completed Last updated 11 April 2023

What this trial tests

trial testing Immunosuppressive in Single Transplant in 92 participants. Completed in 1 May 2022.

Timeline

1 September 2020

Primary endpoint
1 February 2022

1 May 2022

Quick facts

Lead sponsor	University of Rome Tor Vergata
Status	Completed
Study type	OBSERVATIONAL
Enrollment	92
Start date	1 September 2020
Primary completion	1 February 2022
Estimated completion	1 May 2022
Sites	1 location across Italy

Drugs / interventions tested

Immunosuppressive

Conditions studied

Single Transplant — all drugs for Single Transplant →
5 Years of Follow-up After Transplant, in Which an Attempt Was Made to Suspend IS — all drugs for 5 Years of Follow-up After Transplant, in Which an Attempt Was Made to Suspend IS →

Sponsor

University of Rome Tor Vergata

Who can join

Adults 49 to 89, any sex, with Single Transplant or 5 Years of Follow-up After Transplant, in Which an Attempt Was Made to Suspend IS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluate de novo onset of metabolic syndrome, NAFLD and NASH in liver transplant recipients who have discontinued immunosuppressive therapy ("tolerant") and in those taking immunosuppressive therapy ("non-tolerant").

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Immunosuppressive

Trials testing the same drug.

NCT03558373 — The Adherence of Immunosuppressive Therapy Including Tacrolimus Once-daily in Italian Kidney Transplant Recipients · completed

Other University of Rome Tor Vergata trials

Trials by the same sponsor.

NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT07313358 — 10119473 -VIROMARKERS HDV Biomarkers Study · not yet recruiting
NCT07286461 — VIROMARKERS GA n.101194735 - CMV and TTV Biomarkers Study Protocol · not yet recruiting
NCT07067749 — Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer · Phase 3 · recruiting
NCT06711744 — ISQ Differences Between Different Implants in Post-extraction Sockets · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05808192 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Rome Tor Vergata
Last refreshed: 11 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05808192.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing